Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ALLO

Allogene Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ALLO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 02:26 UTC.

What Allogene Therapeutics, Inc. does

The company is a clinical-stage immuno-oncology firm developing genetically engineered allogeneic T cell therapies—off-the-shelf treatments derived from healthy donors rather than individual patients—for cancer and autoimmune diseases. The company has treated more than 200 patients across six clinical studies and focuses on three core programs: cemacabtagene ansegedleucel for large B-cell lymphoma, ALLO-329 for autoimmune diseases, and ALLO-316 for renal cell carcinoma.

Summarized from Allogene Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-61.01%

Revenue, margins & earnings

FY2021: net loss $182M on revenue $114M$114MFY2021FY2022: net loss $340M on revenue $156,000$156,000FY2022FY2023: net loss $327M on revenue $95,000$95,000FY2023FY2024: net loss $258M on revenue $22,000$22,000FY2024
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-25
  • 2026-08-25SVP, General CounselSale-29,697$63.0K
  • 2026-07-06President and CEOStock Option (Right to buy)Award476,190—
  • 2026-07-06President and CEORestricted Stock UnitAward134,530—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Allogene Therapeutics, Inc. do?

The company is a clinical-stage immuno-oncology firm developing genetically engineered allogeneic T cell therapies—off-the-shelf treatments derived from healthy donors rather than individual patients—for cancer and autoimmune diseases.

When did ALLO last file with the SEC?

Allogene Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:26 UTC. This page is also available as JSON at /api/data?ticker=ALLO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ALLO and 5,000+ tickers.

Create a free account — keep ALLO
For your agent
GET /api/data?ticker=ALLO

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt